Work

Abstract LB253: Discovery of A-911, a potent, orally bioavailable 5-HT7 antagonist that promotes DC1-mediated T-cell cross-priming and anti-tumor immunity

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-lb253

Authors: Kenneth D. Bromberg, Jacob Gorman, Jun Guo, Douglas E. Kline, Daniel T. Cohen, Paul Ellis, David Peetz, Luis Rodriguez, Sven Malchow, Cara Hrusch, Ryan Duggan, Min Cheng, Todd Hopkins, Bailin Shaw, Val Manaves, Danli Towne, Sujatha Gopalakrishnan

Institution: AbbVie (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154704230

Cites:

Cited by:

Related to: